Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

intermed medical ltd - alanine 3.48 mg/ml; arginine 3.56 mg/ml; aspartic acid 2.45 mg/ml; calcium 0.005 meq/ml (electrolytes); chlorine 0.048 meq/ml (electrolytes); glucose 25%; glutamic acid 2.58 mg/ml; glycine 1.75 mg/ml; histidine 1.05 mg/ml; isoleucine 2.31 mg/ml; leucine 3.5 mg/ml; lysine 3.68 mg/ml (as lysine acetate with 0.0252meq/ml acetate ions); magnesium 0.005 meq/ml (electrolytes); methionine 0.6 mg/ml; phenylalanine 1.04 mg/ml; phosphorus 0.015 mmol/ml (electrolytes); potassium 0.033 meq/ml (electrolytes); proline 2.52 mg/ml; serine 1.86 mg/ml; sodium 0.04 meq/ml (electrolytes); threonine 1.4 mg/ml; tryptophan 0.7 mg/ml; tyrosine 0.94 mg/ml; valine 1.75 mg/ml - solution for infusion - 3.5 % - active: alanine 3.48 mg/ml arginine 3.56 mg/ml aspartic acid 2.45 mg/ml calcium 0.005 meq/ml (electrolytes) chlorine 0.048 meq/ml (electrolytes) glucose 25% glutamic acid 2.58 mg/ml glycine 1.75 mg/ml histidine 1.05 mg/ml isoleucine 2.31 mg/ml leucine 3.5 mg/ml lysine 3.68 mg/ml (as lysine acetate with 0.0252meq/ml acetate ions) magnesium 0.005 meq/ml (electrolytes) methionine 0.6 mg/ml phenylalanine 1.04 mg/ml phosphorus 0.015 mmol/ml (electrolytes) potassium 0.033 meq/ml (electrolytes) proline 2.52 mg/ml serine 1.86 mg/ml sodium 0.04 meq/ml (electrolytes) threonine 1.4 mg/ml tryptophan 0.7 mg/ml tyrosine 0.94 mg/ml valine 1.75 mg/ml

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

intermed medical ltd - alanine 6.98 mg/ml; arginine 12.27 mg/ml; aspartic acid 5.27 mg/ml; glutamic acid 8.2 mg/ml; glycine 3.85 mg/ml; histidine 3.12 mg/ml; isoleucine 7.6 mg/ml; leucine 12 mg/ml; lysine 6.77 mg/ml; methionine 1.8 mg/ml; phenylalanine 4.27 mg/ml; proline 8.12 mg/ml; serine 4.95 mg/ml; taurine 0.7 mg/ml; threonine 5.12 mg/ml; tryptophan 1.8 mg/ml; tyrosine 0.44 mg/ml; valine 6.73 mg/ml - solution for infusion - 10 % - active: alanine 6.98 mg/ml arginine 12.27 mg/ml aspartic acid 5.27 mg/ml glutamic acid 8.2 mg/ml glycine 3.85 mg/ml histidine 3.12 mg/ml isoleucine 7.6 mg/ml leucine 12 mg/ml lysine 6.77 mg/ml methionine 1.8 mg/ml phenylalanine 4.27 mg/ml proline 8.12 mg/ml serine 4.95 mg/ml taurine 0.7 mg/ml threonine 5.12 mg/ml tryptophan 1.8 mg/ml tyrosine 0.44 mg/ml valine 6.73 mg/ml

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

intermed medical ltd - alanine 4.9 mg/ml; arginine 8.61 mg/ml; aspartic acid 3.7 mg/ml; glutamic acid 5.76 mg/ml; glycine 2.7 mg/ml; histidine 2.2 mg/ml; isoleucine 5.34 mg/ml; leucine 8.31 mg/ml; lysine 4.75 mg/ml; methionine 1.25 mg/ml; phenylalanine 3 mg/ml; proline 5.7 mg/ml; serine 3.47 mg/ml; taurine 0.5 mg/ml; threonine 3.6 mg/ml; tryptophan 1.25 mg/ml; tyrosine 0.44 mg/ml; valine 4.52 mg/ml - solution for infusion - 7 % - active: alanine 4.9 mg/ml arginine 8.61 mg/ml aspartic acid 3.7 mg/ml glutamic acid 5.76 mg/ml glycine 2.7 mg/ml histidine 2.2 mg/ml isoleucine 5.34 mg/ml leucine 8.31 mg/ml lysine 4.75 mg/ml methionine 1.25 mg/ml phenylalanine 3 mg/ml proline 5.7 mg/ml serine 3.47 mg/ml taurine 0.5 mg/ml threonine 3.6 mg/ml tryptophan 1.25 mg/ml tyrosine 0.44 mg/ml valine 4.52 mg/ml

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

biomed limited - alanine 6 mg/ml; arginine 8.1 mg/ml; cysteine hydrochloride monohydrate 0.2 mg/ml; glycine 11.9 mg/ml; histidine 2.4 mg/ml; isoleucine 5.9 mg/ml; leucine 7.7 mg/ml; lysine 8.7 mg/ml (acetate); methionine 4.5 mg/ml; phenylalanine 3.8 mg/ml; proline 9.5 mg/ml; serine 5 mg/ml; threonine 3.4 mg/ml; tryptophan 130 mg/ml; valine 5.6 mg/ml - solution for infusion - 8.5 % - active: alanine 6 mg/ml arginine 8.1 mg/ml cysteine hydrochloride monohydrate 0.2 mg/ml glycine 11.9 mg/ml histidine 2.4 mg/ml isoleucine 5.9 mg/ml leucine 7.7 mg/ml lysine 8.7 mg/ml (acetate) methionine 4.5 mg/ml phenylalanine 3.8 mg/ml proline 9.5 mg/ml serine 5 mg/ml threonine 3.4 mg/ml tryptophan 130 mg/ml valine 5.6 mg/ml

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

biomed limited - alanine 5.4 mg/ml; arginine 12 mg/ml; aspartic acid 3.2 mg/ml; cysteine 0.16 mg/ml; glutamic acid 5 mg/ml; glycine 3.6 mg/ml; histidine 4.8 mg/ml; isoleucine 8.2 mg/ml; leucine 14 mg/ml; lysine 8.2 mg/ml; methionine 3.4 mg/ml; phenylalanine 4.8 mg/ml; proline 6.8 mg/ml; serine 3.8 mg/ml; taurine 0.25 mg/ml; threonine 4.2 mg/ml; tryptophan 2 mg/ml; tyrosine 2.4 mg/ml; valine 7.8 mg/ml - solution for infusion - 10 % - active: alanine 5.4 mg/ml arginine 12 mg/ml aspartic acid 3.2 mg/ml cysteine 0.16 mg/ml glutamic acid 5 mg/ml glycine 3.6 mg/ml histidine 4.8 mg/ml isoleucine 8.2 mg/ml leucine 14 mg/ml lysine 8.2 mg/ml methionine 3.4 mg/ml phenylalanine 4.8 mg/ml proline 6.8 mg/ml serine 3.8 mg/ml taurine 0.25 mg/ml threonine 4.2 mg/ml tryptophan 2 mg/ml tyrosine 2.4 mg/ml valine 7.8 mg/ml excipient: glacial acetic acid sodium metabisulfite water for injection

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - methylphenidate hydrochloride 36mg (drug layer 1, drug layer 2 & drug coat) - modified release tablet - 36 mg - active: methylphenidate hydrochloride 36mg (drug layer 1, drug layer 2 & drug coat) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hypromellose ferric oxide, green (push layer) iron oxide yellow opacode black ns-78-17715 opadry clear ys-1-19025-a opadry white y-30-18037 phosphoric acid poloxamer 188 polyethylene oxide povidone sodium chloride stearic acid succinic acid - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. need for comprehensive treatment programme: concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms. long term use: the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - docetaxel 10 mg/ml - solution for infusion - 10 mg/ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol macrogol 300 nitrogen as needed polysorbate 80 - treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. dbl docetaxel, concentrated injection in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. dbl™ docetaxel, concentrated injection in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.

Ísrael - enska - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - solution for injection - pasireotide as diaspartate 0.6 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Singapúr - enska - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - methylphenidate 31.13mg eqv methylphenidate hcl - tablet, film coated - 36mg - methylphenidate 31.13mg eqv methylphenidate hcl 36mg

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - mercaptopurine 20 mg/ml - oral suspension - 20 mg/ml - active: mercaptopurine 20 mg/ml excipient: aspartame potassium sorbate purified water raspberry flavour - concentrated juice (nova) sodium ethyl hydroxybenzoate sodium hydroxide sodium methyl hydroxybenzoate xanthan gum - allmercap is indicated for the treatment of acute lymphoblastic leukaemia (all) in paediatric patients.